Viking Therapeutics, Inc. (NasdaqCM:VKTX) Boasting a VC1 Score of 61
Checking in on some valuation rankings, Viking Therapeutics, Inc. (NasdaqCM:VKTX) has a Value Composite score of 61. Developed by James O’Shaughnessy, the VC score uses five valuation ratios. These ratios are price to earnings, price to cash flow, EBITDA to EV, price to book value, and price to sales. The VC is displayed as a number between 1 and 100. In general, a company with a score closer to 0 would be seen as undervalued, and a score closer to 100 would indicate an overvalued company. Adding a sixth ratio, shareholder yield, we can view the Value Composite 2 score which is currently sitting at 69.
Many individuals strive to become successful stock market traders. In reality, it can be very difficult for the average trader to stay afloat during the process of learning all the ins a ...